NewAmsterdam Pharma's cholesterol drug combination met key goals in a late-stage study, leading to plans for regulatory approval. The Phase 3 trial showed significant reduction in LDL cholesterol in adults with certain conditions. Regulatory filings will be pursued globally. Trading of NewAmsterdam shares was halted.